Leary and Alpert's dismissal from Harvard

Leary and Alpert’s dismissal from Harvard stands at the boundary between university-based psychedelic research and a movement increasingly concerned with spiritual experience and cultural change. The evidence surrounding the event does not detail the decision itself; it does show that the conflict belonged to a larger struggle over what psychedelic research was for, who could claim authority over it, and whether its aims could remain within conventional medicine.

A Dispute Already Taking Shape

By 1955, Al Hubbard was trying to organize psychedelic researchers beyond medicine’s focus on the ill. His Commission for the Study of Creative Imagination brought together researchers including Humphry Osmond, Abram Hoffer, Aldous Huxley, and Sidney Cohen, alongside a philosopher and a United Nations official. Hubbard called himself its scientific director, though the commission’s practical reach is unclear. Its significance lay partly in the distinction it made visible: psychedelic work could be directed not only toward treatment, but also toward questions of human potential and experience beyond empirical measurement.

The divide was not merely institutional. Sidney Cohen resigned from the commission in 1957, a year after joining, while Hubbard expressed growing dissatisfaction with science pursued as an end in itself. The account places this divergence before Leary’s later prominence: the objective of psychedelic research was already shifting from psychotherapy toward cultural revolution. Leary and Alpert’s departure from Harvard therefore belongs to a conflict whose intellectual terms had been forming across a wider research network.

A Challenge to Psychiatric Convention

The therapeutic model advanced by Osmond, Hubbard, and Huxley in 1956–57 unsettled psychiatry in ways earlier frameworks did not. Psychotomimetic research treated the drugs’ effects as resembling mental illness; psycholytic practice could be incorporated into psychoanalysis as an aid to talking therapy. Psychedelic therapy proposed something more disruptive: a single high-dose session intended to produce a conversion experience, requiring a reconsideration of the roles of both patient and therapist.

That model also brought spiritual language and practice close to clinical work. Its attention to a participant’s set and setting, and to the therapist’s influence, made it difficult to separate the drug from the experience built around it. Later researchers would confront the same problem in trials: participants and guides could often recognize whether psilocybin had been given, while expectation, context, and therapeutic presence complicated efforts to isolate a chemical effect. The controversy around Leary and Alpert thus sits within a sustained dispute over whether psychedelic treatment could be assessed—and authorized—using the ordinary categories of drug research.

From Harvard to Wider Lineages

The later history of underground psychedelic therapy shows that Leary’s influence did not end with his university career. Guides interviewed decades afterward often traced their professional lineage to Leary, frequently through one of his graduate students, as well as to Stanislav Grof, Al Hubbard, or Leo Zeff. This record does not establish the dismissal as the cause of underground practice; it does show how work associated with the Harvard generation persisted through personal transmission after sanctioned psychedelic therapy had ended.

In 2010, James Fadiman asked at a psychedelic-science conference in San Jose whether underground guides were present and invited them to meet the next morning. He expected a handful; about a hundred arrived. Their gathering revealed a dispersed field sharing practices and outlooks, though not a formal organization. The event’s historical resonance lies in this contrast: research could lose its foothold within a university while knowledge and practice continued to travel through networks of students, therapists, and guides.

The Meaning of the Separation

The dismissal is significant within a history in which the boundaries between medicine and spirituality, illness and health, and scientific authority and personal experience repeatedly came under pressure. Psychedelic therapy asked more of the clinician than administering a substance: it depended on the circumstances of the session and on an experience that some researchers described as spiritual. Critics regarded those elements as threats to scientific competence; other practitioners saw them as integral to the treatment.

Later institutional research would return to many of the same questions under contemporary scientific standards, while acknowledging that the therapeutic experience could not easily be reduced to pharmacology alone. The Harvard departure is therefore best understood as a point in a broader separation between institutional legitimacy and a more expansive vision of psychedelic work—not as the beginning of that divide, but as one of its consequential markers.